Drug intelligence / Profile preview

17864

Development stage: Preclinical
Modality: Small Molecules
Administration: Not Established

Overview

Multikinase inhibitor 17864 is a compound referenced in research as a multikinase inhibitor, studied for targeted therapy delivery in cancer models. It has been used in studies where it is conjugated to nanobody-albumin nanoparticles (NANAPs) for the delivery to EGFR (epidermal growth factor receptor) overexpressing tumor cells. Its mechanism involves broad-spectrum kinase inhibition targeting cancer cell signaling pathways, potentially including EGFR-related pathways. Specific clinical or pharmaceutical use, regulatory approval, or commercial development status is not established based on currently available data[2].

Targets

PK (Pyruvate kinase)

Beyond the preview

Go deeper on 17864.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 17864.

Explore the full profile